Aegis Capital initiated coverage of IntelGenx (OTCQX:IGXT) with a “buy” rating and $3 price target. The stock closed at 88 cents on Jan. 26.Read More
BTIG raised its price target for KalVista Pharmaceuticals (NASDAQ:KALV) to $27 from $18 after the company inked a multifaceted collaboration with Merck (NYSE:MRK) last week. The stock closed at $9.74 on Oct. 13.Read More
Roth Capital Partners has resumed coverage of Viralytics (ASX:VLA; OTCQX:VRACY) with a “buy” rating and AUD$2 price target. The stock closed at AUD$1.05 on Jan. 30.Read More
Ladenburg Thalmann upgraded Codexis (NASDAQ:CDXS) to “buy” from “neutral” with a new price target of $6.25. The shares were quoted at $4.65 in afternoon trading on Jan. 4.Read More
Roth Capital Partners raised its price target for Bionomics (ASE:BNO; OTCQX:BNOEF) to (Australian) $2.50 from $1.50 after the company’s Phase 2 BNC210 trial met its primary and secondary endpoints in treating generalized anxiety disorder (GAD) in an acute setting. The stock closed at 27 cents on Tuesday.
Analyst Joseph Pantginis writes that there are two key takeaways from the study: brain systems involved with anxiety are being engaged effectively and the data significantly increase the partnering potential for BNC210. Merck (NYSE:MRK) has already signed two separate partnerships with Bionomics.Read More
The Massachusetts Life Sciences Center (MLSC), Massachusetts General Hospital (MGH) and five leading BioPharma companies have launched the Massachusetts Center for Alzheimer Therapeutics Science (MassCATS) to find therapies for Alzheimer’s disease.
The new center will be located at MGH. Industry partners, including AbbVie, Biogen, Janssen Pharmaceuticals, Merck and Sunovion Pharmaceuticals, have committed $1.25-million in Alzheimer’s-related research funding.Read More
Roth Capital Partners has initiated coverage of Bionomics (OTCQX:BNOEF; ASX:BNO) with a “buy” rating and AUD$1.50 price target. The stock closed at 32 cents on Tuesday.
“We believe a significant disconnect exists on the [company’s] BNC210 opportunity alone based on clinical data in hand and the partnering potential around a drug that could address significant markets,” writes analyst Joseph Pantginis.Read More
H.C. Wainwright has launched coverage of Codexis (NASDAQ:CDXS) with a “buy” rating and $6 price target. The stock closed at $4.23 on Tuesday.
Codexis is a biotechnology services company that specializes in the development of novel, high-efficiency biocatalysts used in manufacturing processes.Read More